Market Overview

UPDATE: Goldman Sachs Upgraded Forest Laboratories to Neutral on Improved Outlook

Related FRX
Icahn's (Potential) Move Into Biotech
Carl Icahn's Track Record In Big Pharma

Goldman Sachs upgraded Forest Laboratories, Inc. (NYSE: FRX) from Sell to Neutral and raised the price target from $33.00 to $40.00.

Goldman Sachs commented, "We upgrade FRX to Neutral from Sell based on a more optimistic view of new products and our view that FRX's industry low margins leave substantial room for earnings appreciation if FRX either grows into its cost base or cuts costs to rationalize it. In either scenario we believe the time horizon for margin improvement is now near enough to warrant an upgrade as FRX begins to monetize a string of new product approvals."

Forest Laboratories closed at $37.30 on Thursday.

Latest Ratings for FRX

May 2014UBSMaintainsNeutral
Apr 2014Cantor FitzgeraldMaintainsHold
Apr 2014SunTrust Robinson HumphreyDowngradesBuyNeutral

View More Analyst Ratings for FRX
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings


Related Articles (FRX)

View Comments and Join the Discussion!

Partner Center